Elevating microRNA levels by targeting biogenesis with steric-blocking antisense oligonucleotides
RNA · 2024
DOI: 10.1261/rna.080021.124 ↗Kurz gefasst
Fachartikel in der Zeitschrift RNA, 2024. Verfasst von Mallory A Havens und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, USA havensm…. Hauptthemen laut MEDLINE: MicroRNAs, Oligonucleotides, Antisense, TRPP Cation Channels. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
MicroRNAs (miRNAs) are regulators of gene expression, and their dysregulation is linked to cancer and other diseases, making them important therapeutic targets. Several strategies for targeting and modulating miRNA activity are being explored. For example, steric-blocking antisense oligonucleotides (ASOs) can reduce miRNA activity by either blocking binding sites on specific mRNAs or base-pairing to the miRNA itself to prevent its interaction with the target mRNAs. ASOs have been less explored as a tool to elevate miRNA levels, which could also be beneficial for treating disease. In this study, using the PKD1 /miR-1225 gene locus as an example, where miR-1225 is located within a PKD1 intron, we demonstrate an ASO-based strategy that increases miRNA abundance by enhancing biogenesis from the primary miRNA transcript. Disruptions in PKD1 and miR-1225 are associated with autosomal dominant polycystic kidney disease (ADPKD) and various cancers, respectively, making them important therapeutic targets. We investigated PKD1 sequence variants reported in ADPKD that are located within the sequence shared by miR-1225 and PKD1, and identified one that causes a reduction in miR-1225 without affecting PKD1 . We show that this reduction in miR-1225 can be recovered by treatment with a steric-blocking ASO. The ASO-induced increase in miR-1225 correlates with a decrease in the abundance of predicted miR-1225 cellular mRNA targets. This study demonstrates that miRNA abundance can be elevated using ASOs targeted to the primary transcript. This steric-blocking ASO-based approach has broad potential application as a therapeutic strategy for diseases that could be treated by modulating miRNA biogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, USA havensmy@lewisu.edu hastingm@umich.edu.
- Biology Department, Lewis University, Romeoville, Illinois 60446, USA.
- Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
- Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, USA.
- Ionis Pharmaceuticals, Carlsbad, California 92008, USA.
Förderung
- NINDS NIH HHS
Zitieren
APA
Havens, M. A., Hinrich, A. J., Rigo, F., & Hastings, M. L. (2024). Elevating microRNA levels by targeting biogenesis with steric-blocking antisense oligonucleotides. RNA. https://doi.org/10.1261/rna.080021.124
Vancouver
Havens MA, Hinrich AJ, Rigo F, Hastings ML. Elevating microRNA levels by targeting biogenesis with steric-blocking antisense oligonucleotides. RNA. 2024. doi:10.1261/rna.080021.124
BibTeX
@article{Havens2024,
author = {Havens, Mallory A and Hinrich, Anthony J and Rigo, Frank and Hastings, Michelle L},
title = {Elevating microRNA levels by targeting biogenesis with steric-blocking antisense oligonucleotides},
journal = {RNA},
year = {2024},
doi = {10.1261/rna.080021.124}
}
EUVIMED